India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology
It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The surgical team used LD Flap Reconstruction, a specialised technique that rebuilt elbow strength and movement
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization
Subscribe To Our Newsletter & Stay Updated
